Fragmin (dalteparin) — Competitive Intelligence Brief

Fragmin (dalteparin) (Fragmin (dalteparin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

phase 3 Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Coagulation Factor Xa and Factor IIa (thrombin) Cardiovascular Small molecule

Target snapshot

Fragmin (dalteparin) (Fragmin (dalteparin)) — Ottawa Hospital Research Institute. Dalteparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factor Xa and thrombin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fragmin (dalteparin) TARGET	Fragmin (dalteparin)	Ottawa Hospital Research Institute	phase 3	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Coagulation Factor Xa and Factor IIa (thrombin)
Receipt of enoxaparin	Receipt of enoxaparin	University of Utah	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III)
Sodium Enoxaparine	Sodium Enoxaparine	Biocad	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III enhancement)
Intermediate dose nadroparin	Intermediate dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (via antithrombin III enhancement)
innohep®	innohep®	LEO Pharma	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
Hepalean Heparin	Hepalean Heparin	McMaster University	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Factors Xa and IIa
Low dose dalteparin	Low dose dalteparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
2. University of Melbourne · 3 drugs in this class
3. French Cardiology Society · 2 drugs in this class
4. Ottawa Hospital Research Institute · 2 drugs in this class
5. McMaster University · 2 drugs in this class
6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
7. GlaxoSmithKline · 1 drug in this class
8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
10. Helsinki University Central Hospital · 1 drug in this class